

Atisnolerbart Biosimilar - Research Grade

Product Code: ICH5230

More Information

Species Reactivity: Human

Target: BETVIA

Concentration: >1mg/ml

Isotype: Human IgG4 - kappa

Host: CHO Cells

product name H2: Atisnolerbart Biosimilar - Research Grade

Antibodies against the same target: [Bremzalerbart Biosimilar - Research Grade \(ICH5231\)](#), [Umesolerbart Biosimilar - Research Grade \(ICH5282\)](#)

Sequence: <https://www.imgt.org/mAb-DB/>

Buffer: ICH3002

Shipping Conditions: Blue ice

background: This catalog entry (ICH5230) is described as a research-grade, unconjugated, non-therapeutic recombinant analog of the originator drug referenced on the card, supplied for research use only and not for human or veterinary use. Like other biosimilar reagents in this range, it is intended to reproduce the antigen-binding character of the originator molecule so that laboratories can run binding, blocking, and control experiments without consuming clinical material. Typical utility for such a reagent includes use as a positive or isotype-matched reference in assay development, as a benchmarking tool alongside novel candidate antibodies, and as a defined input for in-vitro functional and preclinical characterisation. It is offered at low-endotoxin, research-grade purity (routinely under 1 EU/mg, with ultra-low-endotoxin under 0.5 EU/mg options where available) and in bulk

milligram-to-gram quantities to support scale-up and screening workflows. **IMPORTANT:** the originator drug identity and the molecular target on this card could not be independently verified (see flag), so this background is intentionally generic; it should be replaced with target-specific text once the source data is confirmed. The target on this card is listed as "BETVIA", which could not be reconciled with a verified human therapeutic target. The nearest public match is Bet v 1-A, the major pollen allergen of birch (*Betula*), a small cytoplasmic pathogenesis-related plant protein of the Bet v 1 / PR-10 family that acts as a general ligand-binding (steroid/flavonoid carrier) protein and is a dominant driver of birch-pollen allergy and associated oral allergy syndrome cross-reactivity. That plant allergen is not a credible target for a human IgG4-kappa therapeutic biosimilar, so it is almost certainly a placeholder or mislabel rather than the intended antigen. Because the true target is unconfirmed and no UniProt accession is provided, no specific target biology (expression, signalling, or disease role) is asserted here. Accurate target-biology text must be supplied only after the intended human target is verified.

Other names: Major pollen allergen Bet v 1-A

Specificity: Detects human BETVIA

Purification Method: This monoclonal antibody was purified using Protein A

Formulation: Sterile, preservative-free, solution in PBS. BSA and Azide free.

Purity: >95% by SDS-PAGE

Endotoxin: ≤ 1.0 EU/mg as determined by the LAL method

Storage: This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Applications: Functional Assays

Application Notes: This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Use: Products are for research use only. Not for use in diagnostic or therapeutic procedures.

Delivery Time: 4 weeks